0001713210 true --12-31 Q3 0001713210 2021-01-01 2021-09-30 0001713210 2021-11-10 0001713210 2021-09-30 0001713210 2020-12-31 0001713210 2021-07-01 2021-09-30 0001713210 2020-07-01 2020-09-30 0001713210 2020-01-01 2020-09-30 0001713210 us-gaap:CommonStockMember 2019-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001713210 us-gaap:RetainedEarningsMember 2019-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001713210 2019-12-31 0001713210 us-gaap:CommonStockMember 2020-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001713210 us-gaap:RetainedEarningsMember 2020-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001713210 2020-03-31 0001713210 us-gaap:CommonStockMember 2020-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001713210 us-gaap:RetainedEarningsMember 2020-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001713210 2020-06-30 0001713210 us-gaap:CommonStockMember 2020-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001713210 us-gaap:RetainedEarningsMember 2020-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001713210 us-gaap:CommonStockMember 2021-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001713210 us-gaap:RetainedEarningsMember 2021-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001713210 2021-03-31 0001713210 us-gaap:CommonStockMember 2021-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001713210 us-gaap:RetainedEarningsMember 2021-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001713210 2021-06-30 0001713210 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001713210 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001713210 2020-01-01 2020-03-31 0001713210 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001713210 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001713210 2020-04-01 2020-06-30 0001713210 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001713210 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001713210 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001713210 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001713210 2021-01-01 2021-03-31 0001713210 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001713210 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001713210 2021-04-01 2021-06-30 0001713210 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001713210 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001713210 us-gaap:CommonStockMember 2020-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001713210 us-gaap:RetainedEarningsMember 2020-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001713210 2020-09-30 0001713210 us-gaap:CommonStockMember 2021-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001713210 us-gaap:RetainedEarningsMember 2021-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001713210 AATP:AgapeATPInternationalHoldingLimitedMember 2021-09-30 0001713210 AATP:MrHowKokChoongMember AATP:ShareExchangeAgreementMember 2020-05-07 2020-05-08 0001713210 AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember AATP:ShareExchangeAgreementMember 2020-05-08 0001713210 AATP:SubsidiaryCompanyTwoMember 2020-05-08 0001713210 AATP:MrHowKokChoongMember AATP:ShareExchangeAgreementMember 2020-05-08 0001713210 AATP:SubsidiaryCompanyMember 2021-01-01 2021-09-30 0001713210 AATP:SubsidiaryCompanyMember 2021-09-30 0001713210 AATP:SubsidiaryCompanyOneMember 2021-01-01 2021-09-30 0001713210 AATP:SubsidiaryCompanyOneMember 2021-09-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2021-01-01 2021-09-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2021-09-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2021-01-01 2021-09-30 0001713210 AATP:SubsidiaryCompanyFourMember 2021-01-01 2021-09-30 0001713210 AATP:SubsidiaryCompanyFourMember 2021-09-30 0001713210 2020-01-01 2020-12-31 0001713210 AATP:HealthAndWellnessProductsMember 2021-01-01 2021-09-30 0001713210 AATP:HealthAndWellnessServicesMember 2021-07-01 2021-09-30 0001713210 AATP:HealthAndWellnessServicesMember 2020-07-01 2020-09-30 0001713210 AATP:HealthAndWellnessServicesMember 2021-01-01 2021-09-30 0001713210 AATP:HealthAndWellnessServicesMember 2020-01-01 2020-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2021-07-01 2021-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2020-07-01 2020-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2021-01-01 2021-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2020-01-01 2020-09-30 0001713210 AATP:SocialSecurityOrganizationMember 2021-01-01 2021-09-30 0001713210 AATP:MYRCurrencyMember AATP:SocialSecurityOrganizationMember 2021-01-01 2021-09-30 0001713210 AATP:EmployeesProvidentFundMember 2021-01-01 2021-09-30 0001713210 AATP:EmploymentInsuranceSystemMember 2021-01-01 2021-09-30 0001713210 AATP:MYRCurrencyMember AATP:EmploymentInsuranceSystemMember 2021-01-01 2021-09-30 0001713210 AATP:HumanResourceDevelopmentFundMember 2021-01-01 2021-09-30 0001713210 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-09-30 0001713210 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-01 2021-09-30 0001713210 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0001713210 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0001713210 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0001713210 us-gaap:VehiclesMember 2021-01-01 2021-09-30 0001713210 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-01-01 2021-09-30 0001713210 AATP:SurvivorSelectMember 2021-07-01 2021-09-30 0001713210 AATP:SurvivorSelectMember 2020-07-01 2020-09-30 0001713210 AATP:SurvivorSelectMember 2021-01-01 2021-09-30 0001713210 AATP:SurvivorSelectMember 2020-01-01 2020-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2021-07-01 2021-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2020-07-01 2020-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2021-01-01 2021-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2020-01-01 2020-09-30 0001713210 AATP:IonizedCalMagMember 2021-07-01 2021-09-30 0001713210 AATP:IonizedCalMagMember 2020-07-01 2020-09-30 0001713210 AATP:IonizedCalMagMember 2021-01-01 2021-09-30 0001713210 AATP:IonizedCalMagMember 2020-01-01 2020-09-30 0001713210 AATP:OmegaBlendMember 2021-07-01 2021-09-30 0001713210 AATP:OmegaBlendMember 2020-07-01 2020-09-30 0001713210 AATP:OmegaBlendMember 2021-01-01 2021-09-30 0001713210 AATP:OmegaBlendMember 2020-01-01 2020-09-30 0001713210 AATP:BetaMaxxMember 2021-07-01 2021-09-30 0001713210 AATP:BetaMaxxMember 2020-07-01 2020-09-30 0001713210 AATP:BetaMaxxMember 2021-01-01 2021-09-30 0001713210 AATP:BetaMaxxMember 2020-01-01 2020-09-30 0001713210 AATP:VegeFruitFiberMember 2021-07-01 2021-09-30 0001713210 AATP:VegeFruitFiberMember 2020-07-01 2020-09-30 0001713210 AATP:VegeFruitFiberMember 2021-01-01 2021-09-30 0001713210 AATP:VegeFruitFiberMember 2020-01-01 2020-09-30 0001713210 AATP:IronMember 2021-07-01 2021-09-30 0001713210 AATP:IronMember 2020-07-01 2020-09-30 0001713210 AATP:IronMember 2021-01-01 2021-09-30 0001713210 AATP:IronMember 2020-01-01 2020-09-30 0001713210 AATP:YoungFormulaMember 2021-07-01 2021-09-30 0001713210 AATP:YoungFormulaMember 2020-07-01 2020-09-30 0001713210 AATP:YoungFormulaMember 2021-01-01 2021-09-30 0001713210 AATP:YoungFormulaMember 2020-01-01 2020-09-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-07-01 2021-09-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2020-07-01 2020-09-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2021-01-01 2021-09-30 0001713210 AATP:OrganicYouthCarCleansingBarMember 2020-01-01 2020-09-30 0001713210 AATP:MitogizeMember 2021-07-01 2021-09-30 0001713210 AATP:MitogizeMember 2020-07-01 2020-09-30 0001713210 AATP:MitogizeMember 2021-01-01 2021-09-30 0001713210 AATP:MitogizeMember 2020-01-01 2020-09-30 0001713210 AATP:LipomaskMember 2021-07-01 2021-09-30 0001713210 AATP:LipomaskMember 2020-07-01 2020-09-30 0001713210 AATP:LipomaskMember 2021-01-01 2021-09-30 0001713210 AATP:LipomaskMember 2020-01-01 2020-09-30 0001713210 AATP:HyaluronicAcidSerumMember 2021-07-01 2021-09-30 0001713210 AATP:HyaluronicAcidSerumMember 2020-07-01 2020-09-30 0001713210 AATP:HyaluronicAcidSerumMember 2021-01-01 2021-09-30 0001713210 AATP:HyaluronicAcidSerumMember 2020-01-01 2020-09-30 0001713210 AATP:MousseFacialCleanserMember 2021-07-01 2021-09-30 0001713210 AATP:MousseFacialCleanserMember 2020-07-01 2020-09-30 0001713210 AATP:MousseFacialCleanserMember 2021-01-01 2021-09-30 0001713210 AATP:MousseFacialCleanserMember 2020-01-01 2020-09-30 0001713210 AATP:TrimPlusMember 2021-07-01 2021-09-30 0001713210 AATP:TrimPlusMember 2020-07-01 2020-09-30 0001713210 AATP:TrimPlusMember 2021-01-01 2021-09-30 0001713210 AATP:TrimPlusMember 2020-01-01 2020-09-30 0001713210 AATP:PeriodEndMYRMember 2021-09-30 0001713210 AATP:PeriodEndMYRMember 2020-12-31 0001713210 AATP:PeriodEndHKDMember 2021-09-30 0001713210 AATP:PeriodEndHKDMember 2020-12-31 0001713210 AATP:PeriodAverageMYRMember 2021-07-01 2021-09-30 0001713210 AATP:PeriodAverageMYRMember 2020-07-01 2020-09-30 0001713210 AATP:PeriodAverageMYRMember 2021-01-01 2021-09-30 0001713210 AATP:PeriodAverageMYRMember 2020-01-01 2020-09-30 0001713210 AATP:PeriodAverageHKDMember 2021-07-01 2021-09-30 0001713210 AATP:PeriodAverageHKDMember 2020-07-01 2020-09-30 0001713210 AATP:PeriodAverageHKDMember 2021-01-01 2021-09-30 0001713210 AATP:PeriodAverageHKDMember 2020-01-01 2020-09-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2021-03-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2020-12-31 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-07-01 2021-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2020-07-01 2020-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2021-01-01 2021-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2020-01-01 2020-09-30 0001713210 AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember AATP:ShareExchangeAgreementMember 2020-01-01 2020-03-31 0001713210 AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember AATP:ShareExchangeAgreementMember 2020-03-31 0001713210 AATP:MrHowKokChoongMember 2020-03-31 0001713210 srt:MaximumMember 2021-09-30 0001713210 srt:MinimumMember 2021-09-30 0001713210 srt:MaximumMember 2020-09-30 0001713210 srt:MinimumMember 2020-09-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2021-09-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2020-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2021-09-30 0001713210 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001713210 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001713210 AATP:VehicleMember 2021-09-30 0001713210 AATP:VehicleMember 2020-12-31 0001713210 AATP:GreenproCapitalCorpMember 2018-05-17 0001713210 AATP:GreenproCapitalCorpMember 2018-07-30 0001713210 AATP:GreenproCapitalCorpMember 2018-10-16 0001713210 AATP:DSwissIncMember 2020-11-03 0001713210 AATP:DSwissIncMember 2020-12-09 0001713210 srt:DirectorMember 2021-09-30 0001713210 AATP:DirectorsMember 2021-09-30 0001713210 AATP:UnreservedSdnBhdMember srt:MaximumMember 2019-03-10 0001713210 AATP:UnreservedSdnBhdMember srt:MinimumMember 2019-03-10 0001713210 AATP:MrHowKokChoongMember 2021-09-30 0001713210 AATP:UnreservedSdnBhdMember 2020-03-03 0001713210 AATP:MrHowKokChoongMember 2019-12-31 0001713210 AATP:MrHowKokChoongMember 2020-03-31 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 us-gaap:CommonStockMember AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 AATP:DirectorsOfUnreservedInvestmentMember 2021-09-30 0001713210 AATP:DirectorsOfUnreservedInvestmentMember 2020-12-31 0001713210 AATP:PhoenixPlusCorpMember 2021-09-30 0001713210 AATP:PhoenixPlusCorpMember 2020-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-01-01 2021-09-30 0001713210 AATP:AgapeATPAsiaLimitedMember 2020-01-01 2020-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2021-09-30 0001713210 AATP:AgapeATPAsiaLimitedMember 2020-12-31 0001713210 AATP:HostastaySdnBhdMember 2021-01-01 2021-09-30 0001713210 AATP:HostastaySdnBhdMember 2020-01-01 2020-12-31 0001713210 AATP:HostastaySdnBhdMember 2021-09-30 0001713210 AATP:HostastaySdnBhdMember 2020-12-31 0001713210 AATP:RedboyPicturesSdnBhdMember 2021-01-01 2021-09-30 0001713210 AATP:RedboyPicturesSdnBhdMember 2020-01-01 2020-12-31 0001713210 AATP:RedboyPicturesSdnBhdMember 2021-09-30 0001713210 AATP:RedboyPicturesSdnBhdMember 2020-12-31 0001713210 AATP:THThreeTechnologySdnBhdMember 2021-01-01 2021-09-30 0001713210 AATP:THThreeTechnologySdnBhdMember 2020-01-01 2020-12-31 0001713210 AATP:THThreeTechnologySdnBhdMember 2021-09-30 0001713210 AATP:THThreeTechnologySdnBhdMember 2020-12-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2021-01-01 2021-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2020-01-01 2020-12-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2021-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2020-12-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLMember 2021-01-01 2021-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLMember 2020-01-01 2020-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2021-07-01 2021-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2020-07-01 2020-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2021-01-01 2021-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-05-01 2020-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2021-06-30 0001713210 AATP:AgapeSuperiorLivingMember 2021-01-01 2021-06-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-06-29 2020-07-31 0001713210 AATP:AgapeSuperiorLivingMember 2021-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2021-01-01 2021-09-30 0001713210 country:MY 2021-07-01 2021-09-30 0001713210 country:MY 2020-07-01 2020-09-30 0001713210 country:MY 2021-01-01 2021-09-30 0001713210 country:MY 2020-01-01 2020-09-30 0001713210 country:HK 2021-07-01 2021-09-30 0001713210 country:HK 2020-07-01 2020-09-30 0001713210 country:HK 2021-01-01 2021-09-30 0001713210 country:HK 2020-01-01 2020-09-30 0001713210 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-09-30 0001713210 us-gaap:ForeignCountryMember 2021-01-01 2021-09-30 0001713210 us-gaap:DomesticCountryMember 2021-01-01 2021-09-30 0001713210 country:US 2021-09-30 0001713210 country:US 2020-12-31 0001713210 AATP:LabuanMember 2018-12-28 2019-01-02 0001713210 country:MY 2021-09-30 0001713210 country:MY 2020-12-31 0001713210 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AATP:ECommerceCompanyMember AATP:CustomerMember 2021-07-01 2021-09-30 0001713210 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AATP:ECommerceCompanyMember AATP:CustomerMember 2020-07-01 2020-09-30 0001713210 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AATP:ECommerceCompanyMember AATP:CustomerMember 2021-01-01 2021-09-30 0001713210 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AATP:ECommerceCompanyMember AATP:CustomerMember 2020-01-01 2020-09-30 0001713210 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember AATP:ECommerceCompanyMember 2020-01-01 2020-12-31 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:OneVendorMember 2021-07-01 2021-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:TwoVendorMember 2021-07-01 2021-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:OneVendorMember 2020-07-01 2020-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:TwoVendorMember 2020-07-01 2020-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:OneVendorMember 2021-01-01 2021-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:TwoVendorMember 2021-01-01 2021-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:ThreeVendorMember 2021-01-01 2021-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:OneVendorMember 2020-01-01 2020-09-30 0001713210 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember AATP:TwoVendorMember 2020-01-01 2020-09-30 0001713210 AATP:OneSalesDistributorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2021-07-01 2021-09-30 0001713210 AATP:OneSalesDistributorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2020-07-01 2020-09-30 0001713210 AATP:TwoSalesDistributorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2020-07-01 2020-09-30 0001713210 AATP:OneSalesDistributorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-09-30 0001713210 AATP:SalesDistributorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-04-02 0001713210 2021-05-30 2021-05-31 0001713210 AATP:TrainingCenterMember 2021-05-30 2021-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2021-05-31 0001713210 AATP:COVIDNineteenImpactMember 2021-01-01 2021-09-30 0001713210 AATP:DSYWellnessInternationalSdnBhdMember us-gaap:SubsequentEventMember 2021-11-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:MYR

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 2)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended September 30, 2021

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________

 

Commission File Number 333-220144

 

AGAPE ATP CORPORATION

(Exact name of registrant issuer as specified in its charter)

 

Nevada   36-4838886

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1705 - 1708, Level 17, Tower 2, Faber Tower, Jalan Desa Bahagia,
Taman Desa, 58100 Kuala Lumpur, Malaysia.

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code (60) 192230099

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☒ Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes ☐ No ☐

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at November 10, 2021
Common Stock, $0.0001 par value   376,452,047

 

 

 

 

 

 

EXPLANATORY NOTE

 

Agape ATP Corporation is filing this Amendment No. 2 to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on November 12, 2021 (the “Original Filing”), solely to include an assessment and effectiveness conclusion regarding disclosure controls and procedures to Item 4 of the Quarterly Report.

 

Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Amendment also contains new certifications by our chief executive officer and chief financial officer.

 

Except as described above, this Amendment does not amend, update or change any other items or disclosures contained in the Original Filing, and accordingly, this Amendment does not reflect or purport to reflect any information or events occurring after the original filing date or modify or update those disclosures affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings with the SEC.

 

 

 

 

TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:  
  Unaudited Condensed Consolidated Balance Sheets F-1
  Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income F-2
  Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity F-3
  Unaudited Condensed Consolidated Statements of Cash Flows F-4
  Notes to Unaudited Condensed Consolidated Financial Statements F-5 - F-32
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 3
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 14
ITEM 4. CONTROLS AND PROCEDURES 15
PART II OTHER INFORMATION  
ITEM 1 LEGAL PROCEEDINGS 16
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 16
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 16
ITEM 4 MINE SAFETY DISCLOSURES 16
ITEM 5 OTHER INFORMATION 16
ITEM 6 EXHIBITS 17
  SIGNATURES 18

 

2

 

 

PART I FINANCIAL INFORMATION

 

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   September 31,   December 31, 
   2021   2020 
         
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents (Included $22,232 and $37,387 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2021 and December 31, 2020, respectively)  $2,880,677   $3,517,600 
Accounts receivable   -    172,757 
Amount due from related parties   11,147    3,235 
Inventories   475,508    589,814 
Prepaid taxes (Included $1,353 and $11,330 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2021 and December 31, 2020, respectively)   634,395    1,104,495 
Prepayments and deposits, net   172,019    296,370 
Total Current Assets   4,173,746    5,684,271 
           
OTHER ASSETS          
Property and equipment, net  $234,009   $298,309 
Intangible assets, net   4,128    5,826 
Operating right-of-use assets   263,824    394,141 
Investment in marketable securities   200,644    577,035 
Investment in non-marketable securities   1,500    1,500 
Deferred offering costs   264,735    249,525 
Deferred tax assets (Included $8,751 and $0 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2021 and December 31, 2020, respectively)   124,366    - 
Total Other Assets   1,093,206    1,526,336 
           
TOTAL ASSETS  $5,266,952   $7,210,607 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Customer deposits  $183,006   $236,134 
Operating lease liabilities   148,919    154,276 
Other payables and accrued liabilities ($1,257 and $1,904 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of September 30, 2021 and December 31, 2020, respectively)   508,125    647,677 
Income tax payables   26,193    - 
Amount due to a related party   -    455 
Total Current Liabilities   866,243    1,038,542 
           
NON-CURRENT LIABILITIES          
Operating lease liabilities  $117,663   $241,488 
Deferred tax liabilities   -    5,743 
Total Non-current Liabilities   117,663    247,231 
           
TOTAL LIABILITIES  $983,906   $1,285,773 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding   -    - 
Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 376,452,047 shares issued and outstanding as of September 30, 2021 and December 31, 2020   37,645    37,645 
Additional paid in capital   6,440,616    6,440,616 
Accumulated deficit   (2,281,583)   (734,443)
Accumulated other comprehensive income   86,368    181,016 
TOTAL STOCKHOLDERS’ EQUITY   4,283,046    5,924,834 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $5,266,952   $7,210,607 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   2021   2020   2021   2020 
   For the three months ended   For the nine months ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
                 
REVENUE  $201,284   $1,413,063   $806,850   $2,923,271 
REVENUE – RELATED PARTY   -    -    -    13,654 
TOTAL REVENUE   201,284    1,413,063    806,850    2,936,925 
                     
COST OF REVENUE   (36,663)   (186,891)   (149,877)   (658,445)
                     
GROSS PROFIT   164,621    1,226,172    656,973    2,278,480 
                     
SELLING   (82,854)   (159,292)   (299,806)   (268,648)
COMMISSION   (76,817)   (300,957)   (258,030)   (683,455)
GENERAL AND ADMINISTRATIVE   (369,946)   (355,274)   (1,094,042)   (1,029,052)
PROVISION FOR DOUBTFUL ACCOUNTS   -    -    (121,598)   - 
TOTAL OPERATING EXPENSES   (529,617)   (815,523)   (1,773,476)   (1,981,155)
                     
(LOSS) INCOME FROM OPERATIONS   (364,996)   410,649    (1,116,503)   297,325 
                     
OTHER (EXPENSES) INCOME                    
Other (expenses) income, net   (11,643)   86,748    (60,189)   62,963 
Unrealized holding (loss) gain on marketable securities   (209,169)   (24,419)   (374,900)   102,247 
TOTAL OTHER (EXPENSES) INCOME, NET   (220,812)   62,329    (435,089)   165,210 
                     
(LOSS) INCOME BEFORE INCOME TAXES   (585,808)   472,978    (1,551,592)   462,535 
                     
BENEFIT OF (PROVISION FOR) INCOME TAXES   14,543    (57,941)   4,452    (192,008)
                     
NET (LOSS) INCOME   (571,265)   415,037    (1,547,140)   270,527 
                     
OTHER COMPREHENSIVE (LOSS) INCOME                    
Foreign currency translation adjustment   (20,017)   54,952    (94,648)   90,764 
                     
COMPREHENSIVE (LOSS) INCOME  $(591,282)  $469,989   $(1,641,788)  $361,291 
                     
EARNINGS (LOSS) PER SHARE                    
Basic and diluted  $0.00   $0.00   $0.00   $0.00 
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                    
Basic and diluted   376,452,047    376,451,896    376,452,047    376,366,198 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF

CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

                         
   COMMON STOCK   ADDITIONAL      

ACCUMULATED

OTHER

   TOTAL 
  

Number of

shares

  

Par

value

  

PAID IN

CAPITAL

  

ACCUMULATED

DEFICIT

  

COMPREHENSIVE

INCOME

  

STOCKHOLDERS’

EQUITY

 
Balance as of December 31, 2019   376,275,500   $37,628    5,293,082    (1,089,209)   9,785                      4,251,286 
Net loss   -    -    -    (231,750)   -    (231,750)
Foreign currency translation adjustment   -    -    -    -    7,770    7,770 
Balance as of March 31, 2020   376,275,500   $37,628   $5,293,082   $(1,320,959)  $17,555   $4,027,306 
Net income   -    -    -    87,240    -    87,240 
Issuance of common stock in connection with acquisition of Agape Superior Living Sdn Bhd   162,694    16    1,057,492    -    -    1,057,508 
Foreign currency translation adjustment   -    -    -    -    28,042    28,042 
Balance as of June 30, 2020   376,438,194    37,644    6,350,574    (1,233,719)   45,597    5,200,096 
Net income   -    -    -    415,037    -    415,037 
Issuance of common stock in connection with acquisition of Agape Superior Living Sdn Bhd   13,853    1    90,042    -    -    90,043 
Foreign currency translation adjustment   -    -    -    -    54,952    54,952 
Balance as of September 30, 2020   376,452,047   $37,645   $6,440,616   $(818,682)  $100,549   $5,760,128 

 

   COMMON STOCK   ADDITIONAL       ACCUMULATED
OTHER
   TOTAL 
   Number of
shares
   Par
value
  

PAID IN

CAPITAL

   ACCUMULATED
DEFICIT
  

COMPREHENSIVE

INCOME

   STOCKHOLDERS’
EQUITY
 
Balance as of December 31, 2020   376,452,047   $37,645    6,440,616    (734,443)   181,016                        5,924,834 
Net loss   -    -    -    (333,650)   -    (333,650)
Foreign currency translation adjustment   -    -    -    -    (38,284)   (38,284)
Balance as of March 31, 2021   376,452,047   $37,645   $6,440,616   $(1,068,093)  $142,732   $5,552,900 
Net loss   -    -    -    (642,225)   -    (642,225)
Foreign currency translation adjustment   -    -    -    -    (36,347)   (36,347)
Balance as of June 30, 2021   376,452,047    37,645    6,440,616    (1,710,318)   106,385    4,874,328 
Net loss   -    -    -    (571,265)   -    (571,265)
Foreign currency translation adjustment   -    -    -    -    (20,017)   (20,017)
Balance as of September 30, 2021   376,452,047   $37,645   $6,440,616   $(2,281,583)  $86,368   $4,283,046 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”)

 

   2021   2020 
  

For the nine months ended

September 30,

 
   2021   2020 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net (loss) income  $(1,547,140)  $270,527 
Adjustments to reconcile net (loss) income to net cash used in operating activities:          
Depreciation   56,919    36,524 
Amortization   1,482    993 
Amortization of operating right-of-use assets   112,678    70,047 
Unrealized holding loss (gain) on marketable securities   374,900    (102,247)
Deferred tax (benefit) expense   (131,634)   171,586 
Inventory write-down   36,636    - 
Provision for doubtful accounts   121,598    - 
Changes in operating assets and liabilities:          
Accounts receivables   168,019    (271,876)
Amount due from a related party   -    (1,443)
Inventories   90,580    132,939 
Prepaid taxes   431,224    (123,507)
Prepayments and deposits   (4,309)   247,115 
Prepayments and deposits – related party   -    (1,619)
Accounts payable   -    (2,804)
Customer deposits   (44,044)   (1,268,487)
Operating lease liabilities   (111,460)   (69,021)
Other payables and accrued liabilities   (123,082)   167,603 
Income tax payables   26,193    - 
Net cash used in operating activities   (541,440)   (743,670)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment   (3,970)   (4,700)
Purchase of intangible assets   -    (177)
Cash and cash equivalent acquired through acquisition of Agape Superior Living Sdn Bhd   -    1,210,818 
Proceeds from sale of non-marketable securities to a related party   -    70,173 
Net cash (used in) provided by investing activities   (3,970)   1,276,114 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Deferred offering costs   (15,210)   (203,238)
(Advances to) Repayments from related parties   (8,070)   224,342 
Net cash (used in) provided by financing activities   (23,280)   21,104 
           
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS   (68,233)   45,585 
           
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (636,923)   599,133 
           
CASH AND CASH EQUIVALENTS, beginning of period   3,517,600    2,744,457 
           
CASH AND CASH EQUIVALENTS, end of period  $2,880,677   $3,343,590 
           
SUPPLEMENTAL CASH FLOWS INFORMATION          
Income taxes paid  $327,722   $9,101 
Interest paid  $-   $- 
           
SUPPLEMENTAL NON-CASH FLOWS INFORMATION          
Changes in right-of-use assets and lease liabilities due to lease modifications  $3,259   $- 
Initial recognition of right-of-use assets and lease liabilities  $-   $479,838 
Sale of non-marketable securities to a related party in exchange for ASL  $-   $656,495 
Issuance of common stock in exchange for acquisition payment of ASL  $-   $1,057,508 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., an entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. (“ASL”) is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. Upon the establishment of WATP, WATP starts collaborating with ASL to carry out its wellness programs.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

The accompanying unaudited condensed consolidated financial statements reflect the activities of the Company, Agape ATP Corporation (“AATP LB”), Agape ATP International Holding Limited (“AATP HK”), Wellness ATP International Holdings Sdn, Bhd. (“Wellness ATP”), Agape Superior Living Sdn. Bhd. (“ASL”) and its variable interest entity (“VIE”), Agape S.E.A. Sdn. Bhd. (“SEA”) (See Note 3).

 

Details of the Company’s subsidiaries and VIE:

 

     

Subsidiary company

name

 

Place and

date of

incorporation

 

Particulars of

issued capital

 

Principal

activities

 

Proportional of ownership

interest and

voting power

held

 
                         
1.     Agape ATP Corporation   Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each   Investment holding     100 %
                           
2.     Agape ATP International Holding Limited   Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each   Wholesaling of health and wellness products; and health solution advisory services     100 %
                           
3.     Agape Superior Living Sdn. Bhd.   Malaysia,
August 8, 2003
  9,590,598 shares of ordinary share of RM1 each   Health and wellness products and health solution advisory services via network marketing     99.99 %
                           
4.     Agape S.E.A. Sdn. Bhd.   Malaysia,
March 4, 2004
  2 shares of ordinary share of RM1 each   VIE of Agape Superior Living Sdn. Bhd.     VIE  
                           
5.     Wellness ATP International Holdings Sdn, Bhd   Malaysia,
September 11, 2020
  100 shares of ordinary share of RM1 each   The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns     100 %

 

F-5

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND (Continued)

 

Business Overview

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

The Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s annual report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 31, 2021.

 

F-6

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Principles of consolidation

 

The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE.

 

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

Accounts receivable

 

Accounts receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of September 30, 2021 and December 31, 2020, no allowance for doubtful accounts was provided.

 

F-7

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Inventories

 

Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net realizable value. For the three months ended September 30, 2021 and 2020, the Company did not recognize any inventory write-downs. For the nine months ended September 30, 2021 and 2020, the Company recognized inventory write-downs of $36,636 and $0, respectively.

 

Prepaid taxes

 

Prepaid taxes include (i) prepaid income taxes that will either be refundable or utilized to offset future income tax; and (ii) goods and service tax (“GST”) to be refundable.

 

Prepayments and deposits, net

 

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. Allowance for doubtful accounts provided as of September 30, 2021 and December 31, 2020, was $121,322 and $0, respectively.

 

Property and equipment, net

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

      Useful Life  
         
Computer and office equipment     5-7 years  
Furniture & fixtures     6-7 years  
Leasehold improvements     Lease Term  
Vehicle     5 years  

 

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the unaudited condensed consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

 

F-8

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Intangible assets, net

 

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification     Useful Life  
         
Computer software     5 years  

 

Impairment for long-lived assets

 

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of September 30, 2021 and December 31, 2020, no impairment of long-lived assets was recognized.

 

Deferred offering costs

 

Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.

 

Investment in marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss in the caption of “unrealized holding gain loss on marketable securities” in each reporting period.

 

F-9

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Investment in non-marketable equity securities

 

The Company follows the provisions of ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

Customer deposits

 

Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

F-10

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three months ended September 30, 2021 and 2020, the Company recognized $1,361 and $93,322 as forfeited coupon income, respectively. For the nine months ended September 30, 2021 and 2020, the Company recognized $12,587 and $93,322 as forfeited coupon income, respectively.

 

As of September 30, 2021, the Company had contracts for the sales of health and wellness products amounting to $86,364 which it is expected to fulfill within 12 months.

 

F-11

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person.

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three months ended September 30, 2021 and 2020, revenues from health and wellness services were $1,308 and $0 respectively. For the nine months ended September 30, 2021 and 2020, revenues from health and wellness services were $7,054 and $0 respectively.

 

Disaggregated information of revenues by products and services are as follows:

 

                 
   For the three months ended   For the nine months ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
                 
Survivor Select  $14,252   $83,107   $51,893   $119,101 
Energized Mineral Concentrate   49    58,491    52,232    81,097 
Ionized Cal-Mag   15,506    352,718    55,804    850,716 
Omega Blend   48,582    109,258    233,943    271,801 
Beta Maxx   32,605    123,080    122,405    134,514 
Vege-Fruit Fiber   186    1,814    186    7,920 
Iron   4,619    22,581    21,334    135,743 
Young Formula   8,606    378,970    34,507    728,708 
Organic Youth Care Cleansing Bar   -    12,395    2,990    41,200 
Mitogize   68,443    36,914    175,286    41,625 
Lipomask   1,797    33,379    10,198    41,799 
Hyaluronic Acid Serum   836    51,289    4,162    107,010 
Mousse Facial Cleanser   3,565    24,136    11,252    27,263 
Trim+   930    124,931    23,604    348,428 
Health and wellness services   1,308    -    7,054    - 
Total revenues  $201,284   $1,413,063   $806,850   $2,936,925 

 

F-12

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Cost of revenue

 

Cost of revenue includes freight-in, the purchase cost of manufactured goods for sale to customers, and inventory write-downs. Cost of revenue amounted to $36,663 and $186,891 for the three months ended September 30, 2021 and 2020, respectively. Cost of revenue amounted to $149,877 (including inventory write-downs of $36,636) and $658,445 for the nine months ended September 30, 2021 and 2020, respectively.

 

Shipping and handling charges

 

Shipping and handling charges amounted to $2,139 and $3,467 for the three months ended September 30, 2021 and 2020, respectively. Shipping and handling charges amounted to $7,411 and $6,022 for the nine months ended September 30, 2021 and 2020, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

 

Advertising costs

 

Advertising costs amounted to $2,473 and $5,634 for the three months ended September 30, 2021 and 2020, respectively. Advertising costs amounted to $19,131 and $8,516 for the nine months ended September 30, 2021 and 2020, respectively. Advertising costs are expensed as incurred and included in selling expenses.

 

Commission expenses

 

Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $76,817 and $ 300,957 for the three months ended September 30, 2021 and 2020, respectively. Commission expenses amounted to $258,030 and $683,455 for the nine months ended September 30, 2021 and 2020, respectively.

 

Defined contribution plan

 

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $21,674 and $25,442 for the three months ended September 30, 2021 and 2020, respectively. Total expenses for the plans were $74,708 and $49,152 for the nine months ended September 30, 2021 and 2020, respectively.

 

F-13

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The related contribution plans include:

 

  - Social Security Organization (“SOSCO”) – 1.75% based on employee’s monthly salary capped of RM 4,000;
  - Employees Provident Fund (“EPF”) – 12% based on employee’s monthly salary;
  - Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 4,000;
  - Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income taxes for the three months ended September 30, 2021 and 2020. $395 and $0 in penalties and interest incurred related to underpayment of income taxes for the nine months ended September 30, 2021 and 2020, respectively.

 

The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

F-14

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Non-controlling interest

 

Non-controlling interest mainly consists of approximately 0.01% (3 ordinary shares out of 9,590,599 shares) of the equity interests of ASL held by three individuals. The non-controlling interests are presented in the unaudited condensed consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the unaudited condensed consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company. As of September 30, 2021 and December 31, 2020, the non-controlling interest balance was $0 and therefore not presented in the accompanying unaudited condensed consolidated financial statements.

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three and nine months ended September 30, 2021 and 2020, there were no dilutive shares.

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the unaudited condensed consolidated statements of operations and comprehensive Income (Loss).

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the unaudited condensed consolidated balance sheets.

 

F-15

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

   As of 
  

September 30,

2021

  

December 31,

2020

 
         
Period-average MYR : US$1 exchange rate   4.19    4.02 
Period-average HKD : US$1 exchange rate   7.79    7.75 

 

   For the three months ended   For the nine months ended 
  

September 30,

2021

  

September 30,

2020

  

September 30,

2021

  

September 30,

2020

 
                 
Period-average MYR : US$1 exchange rate   4.20    4.20    4.13    4.23 
Period-average HKD : US$1 exchange rate   7.78    7.75    7.77    7.76 

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the unaudited condensed consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

F-16

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Leases

 

Some of the Company’s leases include one or more options to renew, which is typically at the Company’s sole discretion. The Company regularly evaluates the renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications result in re-measurement of the right of use (“ROU”) assets and lease liabilities. Operating ROU assets and lease liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

 

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

F-17

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.

 

In October 2020, the FASB issued ASU 2020-08, “Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs”. The amendments in this Update represent changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021. Early application is not permitted. All entities should apply the amendments in this Update on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.

 

In October 2020, the FASB issued ASU 2020-10, “Codification Improvements”. The amendments in this Update represent changes to clarify the Codification or correct unintended application of guidance that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 for public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.

 

3. VARIABLE INTEREST ENTITY (“VIE”)

 

SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL’s purchases. Its equity at risk was insufficient to finance its activities and 100% of its business is transacted with ASL. Therefore, it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:

 

  a. The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
  b. The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

Accordingly, the accounts of SEA is consolidated in the accompanying unaudited condensed financial statements.

 

F-18

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

3. VARIABLE INTEREST ENTITY (“VIE”) (Continued)

 

The carrying amount of the VIE’s assets and liabilities were as follows:

 

  

September 30,

2021

  

December 31,

2020

 
         
Current assets:          
Cash and cash equivalents  $22,232   $37,387 
Prepaid taxes   1,353    11,330 
Total current assets   23,585    48,717 
           
Other asset – Deferred tax asset   8,751    - 
Total assets  $32,336   $48,717 
           
Current liabilities:          
Accounts payable – intercompany  $49,581   $51,669 
Other payables and accrued liabilities   1,257    1,904 
Total current liabilities   50,838    53,573 
           
Net deficit  $(18,502)  $(4,856)

 

The summarized operating results of the VIE’s are as follows:

 

             
   For the three months ended   For the nine months ended 
  

September 30,

2021

  

September 30,

2020

  

September 30,

2021

  

September 30,

2020

 
                 
Operating revenues  $-   $146,788   $-   $276,280 
Gross profit  $-   $955   $-   $2,328 
Loss from operations  $(4,914)  $(4,171)  $(16,881)  $(7,920)
Net loss  $(4,079)  $(8,627)  $(14,028)  $(26,766)

 

F-19

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

4. BUSINESS COMBINATION

 

On May 8, 2020, the Company entered into a Share Exchange Agreement (“SPA”) with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in ASL, an entity incorporated in Malaysia. Pursuant to the SPA, as amended on July 1, 2020, Mr. How will receive an aggregate consideration of $1,804,046, which was determined based on the net asset carrying value of ASL as at March 31, 2020. The aggregate consideration shall be satisfied by (i) the offset of the Consideration whereby the Company has a loan receivable of $656,495 as of March 31, 2020 due from Mr. How; and (ii) allotment and issuance of common stock of the Company. The Company shall allot and issue 176,547 shares of the Company’s common stock, par value $0.0001, representing approximately 0.0469% of the total issued and outstanding shares in the Company after the issuance of the Shares, which is valued at $1,147,551 based on the closing price of $6.50 of the Company as quoted on the OTC Market on March 31, 2020. In 2020, the Company has issued all 176,547 shares of the Company’s common stock.

 

The Company’s acquisition of ASL was accounted for as a business combination in accordance with ASC 805. The Company has allocated the purchase price of ASL based upon the carrying value of the identifiable assets acquired and liabilities assumed on April 1, 2020 as ASL was under the common control of Mr. How.

 

The following table summarizes the carry value of the identifiable assets acquired and liabilities assumed on the acquisition date, which represents the net purchase price allocation on the date of the acquisition of ASL.

 

   Carry Value 
ASSETS     
Current assets     
Cash  $1,206,493 
Other receivables   33,210 
Other receivables - related parties   219,121 
Inventories   616,880 
Prepaid taxes   1,206,821 
Prepayments and other assets   318,267 
Total current assets   3,600,792 
      
Other assets     
Property and equipment, net   325,648 
Intangible assets, net   6,686 
Deferred taxes asset, net   172,250 
Total other assets   504,584 
      
Total assets  $4,105,376 
      
LIABILITIES AND SHAREHOLDERS’ EQUITY     
Current liabilities     
Accounts payable - related party  $491,628 
Customer deposits   1,600,606 
Other payables and accrued liabilities   209,096 
Total current liabilities   2,301,330 
      
Total liabilities  $2,301,330 
      
Total net assets acquired  $1,804,046 

 

F-20

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

4. BUSINESS COMBINATION (Continued)

 

The following unaudited pro forma combined results of operations presents the Company’s financial results as if the acquisition of ASL had been completed on January 1, 2020. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings which may result from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations that the Company would have recognized had it completed the transaction on January 1, 2020. Future results may vary significantly from the results in this pro forma information because of future events and transactions, as well as other factors.

 

  

For the Nine

Months Ended

 
  

September 30,

2020

 
     
Revenue  $4,178,177 
Cost of revenue   (737,512)
Gross profit   3,440,665 
Total operating expenses   (3,025,438)
Income from operations   415,227 
Other income, net   75,603 
Income before income taxes   490,830 
Provision for income taxes   (242,841)
Net income  $247,989 
Net income per common share - basic and diluted  $0.00 
Weighted average number of common shares outstanding - basic and diluted   376,452,047 

 

5. CASH AND CASH EQUIVALENTS

 

As of September 30, 2021 and December 31, 2020 the Company has $2,880,677 and $3,517,600, respectively, of cash and cash equivalents, which consists of $841,836 and $1,112,147, respectively, of cash in banks and $2,032,119 and $2,391,182, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits for ranged between 1.80% to 2.15% per annum for the three and nine months ended September 30, 2021. The effective interest rate for the time deposits for ranged between 2.95% to 3.25% per annum for the three and nine months ended September 30, 2020.

 

F-21

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

6. ACCOUNTS RECEIVABLE

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
Accounts receivable  $               -   $172,757 
Allowance for doubtful accounts   -    - 
Total  $-   $172,757 

 

7. INVENTORIES

 

Inventories consist of the following:

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
Finished goods  $475,508   $589,814 

 

For the three months ended September 30, 2021 and 2020, the Company didn’t recognize any inventory write-down. For the nine months ended September 30, 2021 and 2020, the Company recognized inventory write-down of $36,636 and $0, respectively.

 

8. PREPAYMENTS AND DEPOSITS

 

   As of
September 30,
2021
   As of
December 31,
2020
 
Receivables from sales distributors  $32,580   $35,302 
Deposits to suppliers   260,761    261,068 
Subtotal   293,341    296,370 
Less: Provision for doubtful accounts   (121,322)   - 
Total  $172,019   $296,370 

 

Movements of allowance for doubtful accounts are as follows:

 

  

For the Three

Months Ended

September 30,
2021

  

For the Nine

Months Ended

September 30,
2021

  

For the Year

End December, 31,
2020

 
             
Beginning balance  $121,622   $-   $                  - 
Addition   -    121,598    - 
Write off   -    -    - 
Exchange rate effect   (300)   (276)   - 
Ending balance  $121,322   $121,322   $- 

 

9. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consist of the following:

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
Computer and office equipment  $82,062   $81,437 
Furniture & fixtures   121,835    126,966 
Leasehold improvements   201,989    210,496 
Vehicle   98,419    102,564 
Subtotal   504,305    521,463 
Less: accumulated depreciation   (270,296)   (223,154)
Total  $234,009   $298,309 

 

Depreciation expense for the three months ended September 30, 2021 and 2020 amounted to $18,740 and $18,808, respectively. Depreciation expense for the nine months ended September 30, 2021 and 2020 amounted to $56,919 and $36,524, respectively.

 

F-22

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

10. INTANGIBLE ASSETS, NET

 

Intangible assets, net, consist of the following:

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
         
Computer software  $34,355   $35,801 
Less: accumulated amortization   (30,227)   (29,975)
Total  $4,128   $5,826 

 

Amortization expense for the three months ended September 30, 2021 and 2020 amounted to $476 and $511, respectively. Amortization expense for the nine months ended September 30, 2021 and 2020 amounted to $1,482 and $993, respectively.

 

11. INVESTMENT IN MARKETABLE SECURITIES

 

  (i)

On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.

     
  (ii)

On July 30, 2018, the Company disposed 20 shares of common stock in Greenpro Capital Corp. for $125 at a purchase price of $6.2613 per share.

     
  (iii)

On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.

     
  (iv)

On November 3, 2020, the Company received dividend of 6,667 shares of common stock in DSwiss Inc. for $76,671 at fair value of $11.50 per share from Greenpro Capital Corp as a result of its Spin-off of DSwiss Inc.’s shares.

     
  (v) On December 9, 2020, the Company received dividend of 16,663 shares of common stock in DSwiss Inc. for $83,315 at fair value of $5 per share from Greenpro Capital Corp as a result of its Spin-off of DSwiss Inc.’s shares.

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
Cost of investment  $577,035   $66,484 
Dividend income from Greenpro Capital Corp.   -    160,062 
Unrealized holding (loss) gain   (374,900)   350,137 
Exchange rate effect   (1,491)   352 
Investment in marketable securities  $200,644   $577,035 

 

12. INVESTMENT IN NON-MARKETABLE SECURITIES

 

The Company invested in Unreserved Sdn Bhd with the investment amount of $863,592 (RM 3,500,000), which approximated 20% of the equity interest of Unreserved Sdn Bhd and is accounted for under the equity method of accounting. On March 10, 2019, Unreserved Sdn Bhd issued additional common stock for working capital. As the Company did not subscribe for the additional common stock, the Company’s equity interest in investee company was diluted from approximately 20.0% to approximately 17.86%. Effective from March 10, 2019, the Company discontinued equity accounting on the investee company. The Company also ceased control over the operations of the investee company on the same date. Accordingly, the investment in investee company was reclassified to investment in non-marketable securities.

 

Unreserved Sdn Bhd was incorporated in Malaysia with 2,500,000 ordinary shares authorized, issued and outstanding. Mr. Lim Hun Soon @ David Lim and Ms. Aniza Helina Akmi Karim are the directors of Unreserved Sdn Bhd. Mr. How Kok Choong was a director of the company from April 30, 2018 to March 27, 2019.

 

F-23

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

12. INVESTMENT IN NON-MARKETABLE SECURITIES (Continued)

 

On March 3, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at the December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. The Company received proceeds of $70,173, and had an amount due from director of $660,464 at March 31, 2020. In May 2020, the entire outstanding balance was settled as part of the consideration in a transaction which the Company had acquired the CEO’s ownership interest of Agape Superior Living Sdn. Bhd.

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.

 

Unreserved Sdn Bhd  As of
September 30,
2021
   As of
December 31,
2020
 
Investment in non-marketable securities  $-   $730,637 
Less: Sale of investment in non-marketable securities   -    (730,637)
Investment in non-marketable securities  $-   $- 
           
Phoenix Plus Corporation          
Cost of investment  $1,500   $1,500 
           
Total  $1,500   $1,500 

 

13. OTHER PAYABLES AND ACCRUED LIABILITIES

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
Professional fees  $166,980   $297,636 
Promotion expenses   35,921    37,433 
Payroll   22,329    23,976 
Commissions   229,022    224,711 
Others   53,873    63,921 
Total  $508,125   $647,677 

 

F-24

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS

 

Related party balances

 

Amount due from related parties

 

Name of Related Party  Relationship  Nature 

As of

September 30, 2021

   As of
December 31, 2020
 
               
Agape ATP (Asia) Limited (“AATP Asia”)  Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia  Expenses paid for AATP Asia  $2,218   $2,227 
Hostastay Sdn. Bhd.  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay  Sublease rent due from Hostastay   4,777    996 
Redboy Pictures Sdn Bhd  Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy Pictures Sdn Bhd  Expenses paid for Redboy Pictures Sdn Bhd   4,152    - 
TH3 Technology Sdn Bhd  Mr. How Kok Choong, the CEO and director of the Company is also the director of TH3 Technology  Expenses paid for TH3 Technology   -    12 
Total        $11,147   $3,235 

 

Amount due to a Related Party

 

Name of Related Party   Relationship   Nature  

As of

September 30, 2021

    As of
December 31, 2020
 
                     
Agape Superior Living Pty Ltd   Mr. How Kok Choong, the CEO and director of the Company   ATP Printing label fees   $              -     $ 455  
Total           $ -     $ 455  

 

F-25

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS (CONT’D)

 

Name of Related Party   Relationship   Nature  

For the Nine Months
Ended

September 30, 2021

   

For the Nine
Months Ended

September 30, 2020

 
                     
Agape Superior Living Pty Ltd (“ASLPL”)   Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of ASLPL   Sale of products   $           -     $ 13,654  
Total           $ -     $ 13,654  

 

Other Income

 

Name of Related Party   Relationship   Nature  

For the Three
Months Ended

September 30, 2021

   

For the Three
Months Ended

September 30, 2020

 
                     
Hostastay Sdn. Bhd.   Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay   Sublease rental income due from Hostastay   $ 1,428     $ 1,443  
Total           $ 1,428     $ 1,443  

 

Name of Related Party   Relationship   Nature  

For the Nine
Months Ended

September 30, 2021

   

For the Nine
Months Ended

September 30, 2020

 
                     
Hostastay Sdn. Bhd.   Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay   Sublease rental income due from Hostastay   $ 4,357     $ 1,443  
Total           $ 4,357     $ 1,443  

 

F-26

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

15. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of September 30, 2021 and December 31, 2020, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of September 30, 2021 and December 31, 2020, there were 1,000,000,000 common stocks authorized and 376,452,047 shares issued and outstanding.

 

In May 2020, the Company issued 162,694 shares of the Company’s common stock in connection with the acquisition of ASL as part of the acquisition payment.

 

In June 2020, ASL made certain adjustments to its March 31, 2020 financial statements. As a result, the net assets carrying value increased by $90,043, which required the issuance of an additional 13,853 shares of the Company’s common stock to fully satisfy the acquisition payment for ASL to Mr. How Kok Choong, CEO and director of the Company. The 13,853 additional shares were issued in July 2020.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of September 30, 2021 and December 31, 2020.

 

Non-controlling interest

 

As of September 30, 2021 and for the three and nine months ended September 30, 2021, no material transactions of non-controlling interest occurred from the operating results from ASL as the Company holds approximately 99.99% of the equity interest in ASL, non-controlling interests that present in ASL is $0 and therefore not presented separately in the accompanying unaudited condensed consolidated financial statements.

 

16. INCOME TAXES

 

The United States and foreign components of income (loss) before income taxes were comprised of the following:

 

   For the three months ended   For the nine months ended 
   September 30,
2021
   September 30,
2020
   September 30,
2021
   September 30,
2020
 
                 
Tax jurisdictions from:                    
Local – United States  $(117,272)  $(96,606)  $(321,567)  $(400,776)
Foreign – Malaysia   (257,590)   719,561    (727,265)   1,033,341 
Foreign – Hong Kong   (210,946)   (149,977)   (502,760)   (170,030)
(Loss) income before income tax  $(585,808)  $472,978   $(1,551,592)  $462,535 

 

F-27

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

The benefit of (provision for) income taxes consisted of the following:

 SCHEDULE OF PROVISION FOR INCOME TAX

   For the three months ended   For the nine months ended 
   September 30,
2021
   September 30,
2020
   September 30,
2021
   September 30,
2020
 
Current:                    
- Local  $-   $-   $(22,205)  $- 
- Foreign   (63,792)   (20,381)   (104,977)   (20,381)
                     
Deferred:                    
- Local   -    -    -    - 
- Foreign   78,335    (37,560)   131,634    (171,627)
Benefit of (provision for) income tax  $14,543   $(57,941)  $4,452   $(192,008)

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan) and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate tax rate of 21% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (“Subpart F”) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of 35%. In addition, the Tax Cuts and Jobs Act imposed a global intangible low-taxed income (“GILTI”) tax, which is a tax on certain off-shore earnings at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are applied.

 

For the three and nine months ended September 30, 2021 and 2020, the Company’s foreign subsidiaries did not generate any income that are subject to Subpart F tax and GILTI tax.

 

For the nine months ended September 30, 2021, the Company re-visited its fiscal 2020 U.S. income taxes and determined its stock dividend from Greenpro Capital Corp as a result of its Spin-off of DSwiss Inc.’s shares in 2020 were subject to Subpart F and GILTI taxes. As a result, the Company incurred additional income taxes expenses of $22,205, including interest and penalty of $395, for the nine months ended September 30, 2021, after utilizing its estimated cumulative net operating losses (“NOL”) of $312,608 as of December 31, 2020. As a result, the Company’s deferred tax assets of estimated NOL of $65,648 were fully utilized and reduced to $0.

 

As of September 30, 2021 and December 31, 2020, the operations in the United States of America incurred approximately $344,000 and $0, respectively, of cumulative NOL which can be carried forward to offset future taxable income or Subpart F and GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of September 30, 2021 and December 31, 2020 were approximately $72,000 and $0, respectively.

 

Malaysia

 

Changes to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandate companies incorporated in Labuan to satisfy the “substantial activity requirements” to qualify for the preferential tax rate of 3% on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the “substantial activity requirements” was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements, the company was subjected to tax at 24% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.

 

F-28

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd and Wellness ATP International Holdings Sdn Bhd. are governed by the income tax laws of Malaysia and the income tax provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the three and nine months ended September 30, 2021 and RM 500,000 (or approximately $125,000) income for the three and nine months ended September 30, 2020, with the remaining balance being taxed at the 24% rate.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:

 

  

As of

September 30,
2021

  

As of

December 31,
2020

 
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $72,192   $- 
Net operating loss carry forwards in Malaysia   152,553    62,678 
Less: valuation allowance   (72,192)   - 
Deferred tax liabilities:          
Depreciation   (28,187)   (68,421)
Deferred tax assets (liabilities), net  $124,366   $(5,743)

 

Uncertain tax positions

 

The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of September 30, 2021 and December 31, 2020, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interest and penalties tax for the three months ended September 30, 2021 and 2020. $395 and $0 in penalties and interest incurred related to underpayment of income taxes for the nine months ended September 30, 2021 and 2020, respectively.

 

F-29

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

For the three months ended September 30, 2021 and 2020, no customer accounted for 10% or more of the Company’s total revenues. For the nine months ended September 30, 2021 and 2020, no customer accounted for 10% or more of the Company’s total revenues.

 

There is no account receivable balance as of September 30, 2021. As of December 31, 2020, receivables from a third-party e-commerce company accounted for approximately 100.0% of the balance of accounts receivable.

 

(b) Major vendors

 

For the three months ended September 30, 2021, two vendors accounted for 69.3% and 26.5% of the Company’s total purchases. For the three months ended September 30, 2020, two vendors accounted for 63.7% and 36.3% of the Company’s total purchases.

 

For the nine months ended September 30, 2021, three vendors accounted for 74.3%, 14.1% and 10.0% of the Company’s total purchases. For the nine months ended September 30, 2020, two vendors accounted for approximately 66.6% and 33.4% of the Company’s total purchases.

 

There are no accounts payable balance as of September 30, 2021 and December 31, 2020.

 

(c) Commission Expenses to Sales Distributors and Stockists

 

For the three months ended September 30, 2021, one sales distributor accounted for 17.8% of the Company’s total commission expense. For the three months ended September 30, 2020, two sales distributors accounted for approximately 10.5% and 10.3% of the Company’s total commission expense.

 

For the nine months ended September 30, 2021, one sales distributor accounted for 19.4% of the Company’s total commission expense. For the nine months ended September 30, 2020, no sales distributor accounted for 10% or more of the Company’s total commission expense.

 

(d) Credit risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of September 30, 2021 and December 31, 2020, $841,836 and $1,112,147 were deposited with financial institutions, respectively, $509,027 and $563,788 of these balances are not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

F-30

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

On April 1, 2020, the Company adopted ASC 842 for ASL’s office space lease and sales and training center as the lease commencement date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $490,000, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

On May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring May 31, 2023 for its office space and expiring August 31, 2023 for its training center. The lease modification required the Company to re-measure the ROU assets and lease liabilities based on the modified leases. The Company recognized a reduction of $3,259 in ROU assets and lease liabilities upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate.

 

As of September 30, 2021, the weighted remaining term of the lease is approximately 1.79 years.

 

The five-year maturity of the Company’s operating lease liabilities is as follow:

 

Twelve Months Ending September 30, 

Operating lease

liabilities

 
2022  $159,866 
2023   120,411 
Thereafter   - 
Total lease payments   280,277 
Less: interest   (13,695)
Present value of lease liabilities  $266,582 

 

Rent expense for the three months ended September 30, 2021 and 2020 was $44,344 and $58,793, respectively. Rent expense for the nine months ended September 30, 2021 and 2020 was $135,865 and $111,465, respectively.

 

Purchase commitments

 

The total future minimum purchase commitment under a non-cancellable purchase contract as of September 30, 2021 for the next five years and thereafter is as follows:

 

Twelve months ending September 30, 

Minimum

purchase

 
2022  $693,900 
2023   693,900 
2024   693,900 
2025   693,900 
2026   693,900 
Thereafter   867,375 
Total minimum purchase commitments required  $4,336,875 

 

As of the date of this report, the Company’s vendor is not able to meet the Company’s minimum purchase commitment of the health and wellness products due to the manufacturing process was being delayed by its vendor.

 

F-31

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES (Continued)

 

Contingencies

 

Legal

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the unaudited condensed consolidated financial statements.

 

COVID-19

 

Since the declaration of the COVID-19 a pandemic on March 11, 2020, by the World Health Organization or WHO, Malaysia has been put through various stages of lockdowns such as (1) full movement control orders (“MCO”), under which, quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia were made mandatory, (2) MCO were eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia and (3) CMCO were further relaxed to Recovery Movement Control Order (“RMCO”). On January 12, 2021, due to a resurgence of COVID-19 cases, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country. February 2021 marked a significant month for Malaysia as all frontline staff of the country, which comprised those in healthcare, police, the Volunteers Department of Malaysia, the Fire and Rescue Department of Malaysia and civil defense sectors were vaccinated. On February 16, 2021, Prime Minister, Tan Sri Muhyiddin Yassin announced that a National COVID-19 Immunisation Plan will be implemented for one year after February 2021, which 80% of the Malaysia population will be vaccinated to achieve herd immunization. On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country was administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunisation Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily, beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population. The government is preparing to shift into an endemic COVID-19 phase where it will not impose wide lockdowns even if cases rise. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, financial impact of the Company’s customers or suspension supplies may be negatively affected, and could continue to negatively affect the demand for the Company’s product;
  the Company may have to provide significant sales incentives to its customers during the outbreak, which may in turn materially adversely affect its financial condition and operating results; and
  any disruption of the Company’s supply chain, logistics providers or customers could adversely impact its business and results of operations, including causing the Company or its suppliers to cease manufacturing for a period of time or materially delay delivery to its customers, which may also lead to loss of its customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at the similar level year over year in 2021 and 2022.

 

19. SUBSEQUENT EVENT

 

On November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies.

 

F-32

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated March 31, 2021, for the year ended December 31, 2020 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., an entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. (“ASL”) is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. On September 15, 2020, WATP entered into a business collaboration agreement with ASL to carry out certain wellness programs.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

The Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

3

 

 

Results of Operation

 

For the three months ended September 30, 2021 and 2020

 

Revenue

 

We generated revenue of $201,284 for the three months ended September 30, 2021 as compared to $1,413,063 for the three months ended September 30, 2020, representing a significant decrease of $1,211,779 or approximately 85.8%. The significant decrease was mainly due to the COVID-19 situation in Malaysia which has turned more severe in the quarter ended September 30, 2021 as compared to the corresponding period in 2020. As such, it has adversely affected us. From CMCO, the entire country was again placed under full lockdown effective May 12, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since October 3, 2021. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated. The lockdowns disrupted much of our operational activities, which led to the significant decrease in revenue for the three months ended September 30, 2021 as compared to the same period in 2020. Economically, the prolonged pandemic will adversely affect the purchasing power of consumers in Malaysia.

 

Cost of Revenue

 

Cost of revenue for the three months ended September 30, 2021 amounted to $36,663 as compared to $186,891 for the three months ended September 30, 2020, representing a significant decrease of $150,228 or approximately 80.4%. The cost of revenue comprised freight-in, cost of goods purchased, and packing materials. The significant decrease in cost of revenue for the three months ended September 30, 2021 as compared to the same period in 2020, was in line with the significant decrease in our revenues. As explained in the above, much of our operational activities was disrupted as a result of the resurgence of COVID-19 infection and movement control orders imposed in Malaysia as explained above.

 

Gross Profit

 

Gross profit for the three months ended September 30, 2021 amounted to $164,621 as compared to $1,226,172 for the three months ended September 30, 2020. Gross margin for the three months ended September 30, 2021 was approximately 81.8% as compared to approximately 86.8% for the three months ended September 30, 2020. As explained in the above, the decrease in gross profit was attributed to the significant decrease in revenue due to the disruption of our operational activities. In its effort to boost sales, the Company also lowered its product gross margin during the quarter. The Company did not achieve the results that we initially forecasted due to the severity of the COVID-19 situation in the Malaysia as explained above.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses, general and administrative expenses and provision for doubtful accounts.

 

Selling expenses

 

Selling expenses for the three months ended September 30, 2021 amounted to $82,854 as compared to $159,292 for the three months ended September 30, 2020, a decrease of $76,438 or approximately 48.0%. The decrease was mainly due to fewer promotional activities performed in the face of the severity of the COVID-19 pandemic.

 

Commission expenses

 

Commission expenses were $76,817 and $300,957 for the three months ended September 30, 2021 and 2020, respectively, representing a significant decrease of $224,140 or approximately 74.5%. The significant decrease in commission expenses was in line with the significant decrease in revenue.

 

4

 

 

General and administrative expenses

 

General and administrative expenses for the three months ended September 30, 2021 amounted to $369,946, as compared to $355,274 for the three months ended September 30, 2020, representing an increase of $14,672 or approximately 4.1%. The increase was mainly due to the increase of professional fees for the preparation of the Company’s U.S. tax return.

 

Other (Expenses) Income

 

For the three months ended September 30, 2021, we recorded an amount of $220,812 as other expenses, net as compared to $62,329 other income, net for the three months ended September 30, 2020, representing a significant decrease of $283,141 or approximately 454.3%. The net other expenses of $220,812 incurred during the three months ended September 30, 2021 comprised of other expense of $11,643 and unrealized holding loss on marketable securities of $209,169. The net other income of $62,329 incurred during the three months ended September 30, 2020 comprised other income of $86,748 and unrealized holding loss on marketable securities of $24,419.

 

Benefit of (Provision for) Income Taxes

 

We recognized benefit of income taxes $14,543 and provision for income taxes $57,941 for the three months ended September 30, 2021 and 2020, respectively. During the three months ended September 30, 2021, we mainly recognized our ASL’s taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits. On the other hand, during the three months ended September 30, 2020, we generated taxable income in ASL that was subjected to a unified 24% income tax rate.

 

Net (Loss) Income

 

We incurred a net loss of $571,265 for the three months ended September 30, 2021, from a net income of $415,037 for the three months ended September 30, 2020, a decrease of $986,302, predominately due to reasons as discussed above.

 

For the nine months ended September 30, 2021 and 2020

 

Revenue

 

We generated revenue of $806,850 for the nine months ended September 30, 2021 as compared to $2,936,925 for the nine months ended September 30, 2020, representing a significant decrease of $2,130,075 or approximately 72.5%. It is to be noted that as between the two nine-months period, ASL contributed revenue throughout the entire nine months ended September 30, 2021, whereas ASL’s revenue contribution to us only began from April 1, 2020 to September 30, 2020, after the acquisition on May 8, 2020. For the period from January 1, 2020 to March 31, 2020, we were only making sales to our related party on wholesale basis when ASL placed the purchase orders. Despite a full nine months revenue contribution from ASL, which brought us a large group of customers in an established network marketing sales channel that has been in established in Malaysia for the past 15 years, the $2,130,075 reduction in revenue for the nine months ended September 30, 2021, was due to the COVID-19 situation in Malaysia which has turned more severe as explained above. From CMCO, the entire country was again placed under full lockdown effective May 12, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since October 3, 2021. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated. The lockdowns disrupted much of our operational activities, which led to the significant decrease in revenue for the nine months ended September 30, 2021 as compared to the same period in 2020. Economically, the prolonged pandemic will adversely affect the purchasing power of consumers in Malaysia.

 

Cost of Revenue

 

Cost of revenue for the nine months ended September 30, 2021 amounted to $149,877 as compared to $658,445 for the nine months ended September 30, 2020, representing a significant decrease of $508,568 or approximately 77.2%.

 

The cost of revenue comprised freight-in, cost of goods purchased, and packing materials. The significant decrease in cost of revenue for the nine months ended September 30, 2021 as compared to the same period in 2020, was in line with the significant decrease in our revenues. As explained in the above, much of our operational activities was disrupted as a result of the resurgence of COVID-19 infection and movement control orders imposed in Malaysia as explained above.

 

5

 

 

Gross Profit

 

Gross profit for the nine months ended September 30, 2021 amounted to $656,973 as compared to $2,278,480 for the nine months ended September 30, 2020. Gross margin for the nine months ended September 30, 2021 was approximately 81.4% as compared to approximately 77.6% for the nine months September 30, 2020. Gross margin for the two nine months period is less comparable due to (i) change in our business activities from wholesale business to retail activities effective April 1, 2020. Typically, selling our products directly to the customers in the network channel generates higher gross margins as compared to gross margins from our sales to our related party wholesales customers; and (ii) the adverse economic impact brought about by the COVID-19 pandemic. We had to adhere to the MCO which disrupted our operations for the nine months ended September 30, 2021.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses, general and administrative expenses and provision for doubtful accounts.

 

Selling expenses

 

Selling expenses for nine months ended September 30, 2021 amounted to $299,806 as compared to $268,648 for the nine months ended September 30, 2020, representing an increase of $31,158 or approximately 11.6%. The increase was mainly due to selling expenses incurred for the nine months ended September 30, 2021 encompassed selling expenses incurred by ASL for the entire nine months period, whereas selling expenses for the corresponding period last year in connection to ASL’s retail activities only began form April 1, 2020 to September 30, 2020 after its acquisition on May 8, 2020. The Company incurred higher salaries and benefits expenses for the current nine months period, as it represented a full nine months from January 1, 2021 to September 30, 2021, but lower other selling expenses as compared to the corresponding period last year where we incurred selling expenses from ASL from April 1, 2020 to September 30, 2020.

 

Commission expenses

 

Commission expenses were $258,030 and $683,455 for the nine months ended September 30, 2021 and 2020, respectively, representing a significant decrease of $425,425 or approximately 62.2%. The significant decrease in commission expenses was in line with the decrease in revenue as our sales activities was disrupted due to the many lockdowns imposed by the government of Malaysia as a direct result of the resurgence of COVID-19 infections in Malaysia as explained above.

 

General and administrative expenses

 

General and administrative (“G&A”) expenses for nine months ended September 30, 2021, amounted to $1,094,042 as compared to $1,029,052 for the nine months ended September 30, 2020, an increase of $64,990 or approximately 6.3%. G&A expenses for nine months ended September 30, 2021 encompassed G&A expenses incurred by ASL for the entire nine months period, whereas G&A expenses for the corresponding period last year in connection to ASL’s retail activities only began from April 1, 2020 to September 30, 2020, after its acquisition on May 8, 2020.

 

G&A expenses increased marginally, by approximately 6.3%, as most G&A expenses incurred for the nine months ended September 30, 2020 were directly related to the acquisition of ASL, which exercise was completed in April in 2020. The expenses were therefore not expected to recur.

 

G&A expenses for the nine months ended September 30, 2021 comprised of professional fees of $303,880 for legal counsel, auditor, and financial reporting consultant in the U.S. and Hong Kong, to strengthen our current Securities and Exchange Commission (“SEC”) listing reporting documents and continue to stay compliant, salary and employee benefit expenses of $464,494, rental expenses of $135,865, depreciation expenses of $56,919 and other general and administrative expenses of $132,884.

 

G&A expenses for the nine months ended September 30, 2020 comprised of professional fees of $486,870 for legal counsel, auditor, and financial reporting consultant in the U.S. and Hong Kong, to strengthen our current Securities and Exchange Commission (“SEC”) listing reporting documents and continue to stay compliant, salary and employee benefit expenses of $275,068, rental expenses of $111,465, travelling expenses for our CEO for potential business developments of $34,000, depreciation expenses of $36,524 and other general and administrative expenses of $85,125.

 

6

 

 

Provision for doubtful accounts

 

Provision for doubtful accounts were $121,686 and $0 for the nine months ended September 30, 2021 and 2020, respectively, a significant increase of $121,686 or 100.0%. The provision for doubtful accounts was in respect of prepayments to a supplier. As the prepayments remain outstanding for over a year, the likelihood of recovering the prepayments is remote.

 

Other Income (Expenses)

 

For the nine months ended September 30, 2021, we recorded an amount of $435,089 as other expenses, net, as compared to $165,210 other income, net, for the nine months ended September 30, 2020, representing a significant decrease of $600,299 or approximately 363.4%. The net other expenses of $435,089 incurred during the nine months ended September 30, 2021 comprised of other expenses of $60,189 and unrealized holding loss on marketable securities of $374,900. The net other income of $165,210 recognized during the nine months ended September 30, 2020 comprised other income of $62,963 and unrealized holding gain on marketable securities of $102,247.

 

Benefit of (Provision for) Income Taxes

 

We recorded benefit of income taxes $4,452 and provision for income taxes $192,008 for the nine months ended September 30, 2021 and 2020, respectively. During the nine months ended September 30, 2021, we mainly recognized our ASL’s taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits. On the other hand, during the nine months ended September 30, 2020, we generated taxable income in ASL that was subjected to a unified 24% income tax rate.

 

Net Income (Loss)

 

We had net loss of $1,547,140 for the nine months ended September 30, 2021, compared with net income of $270,527 for the nine months ended September 30, 2020, , mainly due to reasons as discussed above.

 

7

 

 

Liquidity and Capital Resources

 

On March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic. To help counter the transmission of COVID-19, the government of Malaysia initiated movement control orders (“MCO”), the first effective March 18, 2020. The MCO had resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia. The first MCO was extended three times, each for a two-weeks period, until May 12, 2020. On May 13, 2020, the MCO was eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia. The CMCO was further relaxed, and on June 8, 2020, Malaysia moved into the Recovery Movement Control Order (“RMCO”). Due to a resurgence of COVID-19, CMCO was reimposed in the state of Sabah, Selangor, Kuala Lumpur and Putrajaya effective October 14, 2020. On November 7, 2020, the CMCO was extended to a wider geographical area to include another six states in the country. Effectively, ten of thirteen states in Malaysia were placed under CMCO with the exceptions of Perlis, Pahang and Kelantan. On January 1, 2021, the Government of Malaysia extended the Recovery Movement Control Order (“RMCO”) through March 31, 2021. On January 12, 2021, the Malaysian government declared a state of emergency nationwide to combat COVID-19. Intermittent lockdowns were imposed in various states and districts in the country.

 

On March 5, 2021, lockdowns in most part of the country was eased to a CMCO, nevertheless, COVID-19 cases in the country continue to rise. On May 12, 2021, Malaysia was again put under a full lockdown nationwide, until the earlier of (i) daily COVID-19 cases infection of the country fall below 4,000; (ii) intensive Unit Care, or ICU, wards start operating at a moderate level; or (iii) 10% of the Malaysian population is fully vaccinated. The country is administering over 400,000 doses of COVID-19 vaccines daily. On July 17, 2021, the full lockdown was slightly eased as 13.9% of the Malaysian population was fully vaccinated, with another 30% having received at least one dose of the vaccine. The COVID-19 situation in the country showed no sign of abating. Kuala Lumpur and Selangor remained the epicenter of the latest wave of infections. Total COVID-19 cases in the country surpassed the one million mark on July 25, 2021, and daily cases hit a record high of 24,599 on August 26, 2021. Despite the deteriorating COVID-19 state, the government lifted Kuala Lumpur from Enhanced Movement Control Order (“EMCO”) ahead of schedule and ended the nationwide state of emergency on August 1, 2021. Parliament met for the first time this year on July 26, 2021. Malaysia pressed on with its National COVID-19 Immunization Plan, fast inoculating its residents. COVID-19 infection started to drop below the 10,000 mark daily since beginning October 3, 2021. Effective October 11, 2021, interstate and international travel restrictions were lifted for residents who had been fully vaccinated against COVID-19 as the country achieved its target of inoculating 90% of its adult population. The government is preparing to shift into an endemic COVID-19 phase where it will not impose wide lockdowns even if cases rise. As of October 31, 2021, over 75% of the country’s population have been fully vaccinated.

 

8

 

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially resulting in which the demand for our products may be adversely affected;
  we may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect our financial condition and operating results; and
  any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers.

 

Although some of the countries from which our products are sourced are experiencing lockdowns, industries involve in the provision of food especially health products and pharmaceuticals are normally exempted. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the setback should be temporary.

 

We currently operate primarily in Malaysia and anticipate expanding into the Asian markets in the future, with a particular focus, at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. When the pandemic has subsided or is over and restrictions on travelling between nations are uplifted, we will set up offices in the countries in which we operate to better service our customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in the remaining period of 2021 and in 2022.

 

As of September 30, 2021, we had working capital of $3,307,503 consisting of cash in bank of $847,773 and time deposits of $2,032,119 as compared to working capital of $4,645,729 consisting of cash in bank of $1,112,147 and time deposits of $2,391,182 as of December 31, 2020. In assessing our liquidity, we monitor and analyze our cash on-hand and our operating expenditure commitments. Our liquidity needs are to meet our working capital requirements and operating expenses obligations. We believe we will have sufficient resource to fund our working capital needs for the next 12 months from the date of issuance of this Form 10-Q.

 

9

 

 

The following summarizes the key components of our cash flows for the nine months ended September 30, 2021 and 2020:

 

   For the Nine Months Ended 
   September 30, 2021   September 30, 2020 
Net cash used in operating activities  $(541,440)  $(743,670)
Net cash (used in) provided by investing activities   (3,970)   1,276,114 
Net cash (used in) provided by financing activities   (23,280)   21,104 
Effect of exchange rate on cash and cash equivalents   (68,233)   45,585 
Net change in cash and cash equivalents  $(636,923)  $599,133 

 

Operating activities

 

Net cash used in operating activities for the nine months ended September 30, 2021 was $541,440 and were mainly comprised of the net loss of $1,547,140, deferred tax benefit of $131,634, decrease in prepayments and deposits of $4,309, decrease in customer deposits of $44,044, payment of operating lease liabilities of $111,460 and decrease in other payables and accrued liabilities of $123,082. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization expense of $58,401, amortization of operating right-of-use assets of $112,678, unrealized holding loss on marketable securities of $374,900, inventories write-down of $36,636, provision for doubtful accounts of $121,598, decrease in accounts receivables of $168,019, decrease in inventories of $90,580, refund in prepaid taxes of 431,224 and decrease in income tax payables of $26,193.

 

Net cash used in operating activities for the nine months ended September 30, 2020 was $743,670 and were predominately comprised of the non-cash income on unrealized holding gain on marketable securities of $102,247, increase in accounts receivables of $271,876, increase in amount due from a related party of $1,443, increase in prepaid taxes of $123,507, decrease in customer deposits of $1,268,487, payment of operating lease liabilities of $69,021 and decrease in accounts payable of $2,804. The net cash used in operating activities was mainly offset by net income of $270,527, non-cash depreciation and amortization expense of $37,517, amortization of operating right-of-use assets of $70,047, deferred tax provision of $171,586, decrease in inventories of $132,939, decrease in prepayments and deposits, including related party of $245,496, and increase in other payables and accrued liabilities of $167,603.

 

Investing activities

 

Net cash used in investing activities for the nine months ended September 30, 2021 was $3,970, which was in respect of purchase of equipment.

 

Net cash provided by investing activities for the nine months ended September 30, 2020 was $1,276,114, which were in respect of cash and cash equivalents acquired through acquisition of ASL of $1,210,818 and partial proceeds collected from the sale of our non-marketable securities of $70,173, offset by purchase of equipment and intangible assets of $4,877.

 

10

 

 

Financing activities

 

Net cash used in financing activities for the nine months ended September 30, 2021 was $23,280 which were mainly comprised of payment of deferred offering cost of $15,210 and advances to related parties of $8,070.

 

Net cash provided by financing activities for the nine months ended September 30, 2020 was $21,104 which were mainly comprised of repayments from related parties of $224,342 offset by payment of deferred offering cost of $203,238.

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2021, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

Critical Accounting Polices

 

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Revenue recognition

 

The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

11

 

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

The Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers during the consultation section in person. The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp.

 

12

 

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

13

 

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.

 

In October 2020, the FASB issued ASU 2020-08, “Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs”. The amendments in this Update represent changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021. Early application is not permitted. All entities should apply the amendments in this Update on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.

 

In October 2020, the FASB issued ASU 2020-10, “Codification Improvements”. The amendments in this Update represent changes to clarify the Codification or correct unintended application of guidance that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 for public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively. The adoption of this standard on January 1, 2021 did not have a material impact on its unaudited condensed consolidated financial statements.

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Foreign exchange risk. Substantially most of our revenues are denominated in the U.S. dollar while most of our expenses are denominated in Malaysian Ringgit and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general, our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign exchange rate between U.S. dollar and Malaysian Ringgit; and U.S. dollar and Hong Kong Dollar because the value of our business is effectively denominated in Malaysian Ringgit and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.

 

Credit risk. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

14

 

 

ITEM 4 CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this Report, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures(as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on the foregoing evaluation, our chief executive officer and chief financial officer concluded that, as at September 30, 2021, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below. 

 

Internal Control Over Financial Reporting

 

Our management, including our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s chief executive officer and chief financial officer and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

 

  Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
     
  Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
     
  Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

As of September 30, 2021, our management, including our chief executive officer and chief financial officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on such evaluation, the Company’s management, including our chief executive officer and chief financial officer, concluded that, during the period covered by this Report, internal controls and procedures over financial reporting were not effective. This was due to deficiencies that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

 

Identified Material Weakness

 

A material weakness in internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

 

Management, including our chief executive officer and chief financial officer, identified the following material weakness during its assessment of internal controls over financial reporting as of September 30, 2021: (i) we did not have sufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP; (ii) we lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures; lack of adequate policies and procedures in internal audit function to ensure that our policies and procedures have been carried out as planned; (iii) we do not have adequate segregation of duties and effective risk assessment. Lack of segregation of duties and effective risk assessment may cause us to face the likelihood of fraud or theft, due to poor oversight, governance and review to detect errors; (iv) we lack of proper procedures developed for system change management policies. Critical change management control processes and procedures, such as change request and approval, periodic status reporting, user testing and acceptance, post-implementation review, etc., were either not performed or formally documented; (v) we lack of the following internal control procedures in relation of System and Data Security Access: (a) authorization of new operating system-level user accounts created was not formally documented, (b) periodic review and recertification of application, operating system, and database users and the user access rights was not performed, (c) procedures for periodic review and analysis of application, operating system, and database-level audit logs were not documented or performed, manually or through the use of software tools, (d) mandatory password settings, such as minimum length, complexity, reset frequency, failed log-in attempts, password history, etc., were not deployed; and (vi) we lack of qualified person to be able to provide the tax provision for the U.S. income taxes in connection with the Subpart F and GILTI taxable income.

 

15

 

 

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

 

Management’s Remediation Initiatives

 

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written policies and procedures for accounting and financial reporting with respect to the requirements and application of both U.S. GAAP and SEC guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity and debt transactions.

 

We have initiated and plan to initiate the following series of measures to further strengthen the Company’s internal controls going forward:

 

1. On January 12, 2021, the Company has appointed a Chief Finance Officer with appropriate levels of accounting knowledge and experience to monitor the recording of transactions, address complex U.S. GAAP accounting issues and to review financial statements and related disclosures under U.S. GAAP.
   
2. We intend to establish an internal audit function with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal control.
   
3. We intend to engage an external consulting firm to supplement our efforts to the implementation of the 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework for internal controls.
   
4. Once we hire additional employees, we intend to initiate a comprehensive training program and development plan to provide ongoing company-wide trainings regarding internal control and requirements of U.S. GAAP financial statements and related disclosures, with particular emphasis on our accounting staff.
   
5. We are seeking a U.S. tax professional to assist in the preparation of the Subpart F and GILTI tax provisions

 

We anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2021.

 

Changes in Internal Control over Financial Reporting:

 

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest averse to us.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

16

 

 

ITEM 6. Exhibits

 

Exhibit No.   Description
31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
     
32.1   Section 1350 Certification of principal executive officer *
     
101.INS   Inline XBRL Instance Document*
     
101.SCH   Inline XBRL Schema Document*
     
101.CAL   Inline XBRL Calculation Linkbase Document*
     
101.DEF   Inline XBRL Definition Linkbase Document*
     
101.LAB   Inline XBRL Label Linkbase Document*
     
101.PRE   Inline XBRL Presentation Linkbase Document*
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

17

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AGAPE ATP CORPORATION
  (Name of Registrant)
     
Date: July 5, 2022    
  By: /s/ How Kok Choong
  Title:

Chief Executive Officer,

    President, Director, Secretary and Treasurer

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AGAPE ATP CORPORATION
  (Name of Registrant)
     
Date: July 5, 2022    
  By: /s/ Andrew Lee Kam Fan
  Title:

Chief Financial Officer,

 

18

Agape ATP (PK) (USOTC:AATP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Agape ATP (PK) Charts.
Agape ATP (PK) (USOTC:AATP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Agape ATP (PK) Charts.